Psychopharmacology: From serendipitous discoveries to rationale design, but what next?

Brain and neuroscience advances Pub Date : 2018-11-22 eCollection Date: 2018-01-01 DOI:10.1177/2398212818812629
Emma Robinson
{"title":"Psychopharmacology: From serendipitous discoveries to rationale design, but what next?","authors":"Emma Robinson","doi":"10.1177/2398212818812629","DOIUrl":null,"url":null,"abstract":"<p><p>Psychopharmacology really developed as a discipline from the mid-20th century with the discovery of a number of new classes of psychoactive drugs which could modify behaviour. These drugs were discovered as a consequence of clinical observations of patients, often being treated for other conditions. These serendipitous discoveries were the start of an era of drug development which has led to the antidepressants, antipsychotics, anxiolytics and mood stabilisers used today. Subsequent research focused on understanding why these drugs were effective, and used this information to develop a second generation of drugs that were more selective for their therapeutic targets, and therefore had reduced side effects and improved safety and tolerability. After a period of decline in new discoveries and withdrawal of the majority of the major pharmaceutical companies from active development programmes in psychiatry, new avenues are emerging fuelling renewed interest in this area.</p>","PeriodicalId":72444,"journal":{"name":"Brain and neuroscience advances","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2398212818812629","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain and neuroscience advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2398212818812629","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Psychopharmacology really developed as a discipline from the mid-20th century with the discovery of a number of new classes of psychoactive drugs which could modify behaviour. These drugs were discovered as a consequence of clinical observations of patients, often being treated for other conditions. These serendipitous discoveries were the start of an era of drug development which has led to the antidepressants, antipsychotics, anxiolytics and mood stabilisers used today. Subsequent research focused on understanding why these drugs were effective, and used this information to develop a second generation of drugs that were more selective for their therapeutic targets, and therefore had reduced side effects and improved safety and tolerability. After a period of decline in new discoveries and withdrawal of the majority of the major pharmaceutical companies from active development programmes in psychiatry, new avenues are emerging fuelling renewed interest in this area.

Abstract Image

Abstract Image

Abstract Image

精神药理学:从偶然发现到基本原理设计,下一步是什么?
精神药理学真正发展成为一门学科是从20世纪中期开始的,当时发现了一些可以改变行为的新型精神药物。这些药物是在对患者的临床观察中发现的,通常用于治疗其他疾病。这些偶然的发现开启了一个药物开发时代,导致了今天使用的抗抑郁药、抗精神病药、抗焦虑药和情绪稳定剂。随后的研究重点是了解这些药物为什么有效,并利用这些信息开发第二代药物,这些药物对其治疗靶点更具选择性,因此副作用更少,安全性和耐受性更高。经过一段时间的新发现下降和大多数主要制药公司退出精神病学的积极发展计划后,新的途径正在出现,促使人们对这一领域重新产生兴趣。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信